What Should I Ask a Neuro-Ophthalmologist About ADOA?

Finding the right specialist is one of the most important steps in managing Autosomal Dominant Optic Atrophy (ADOA). A neuro-ophthalmologist—a doctor who specializes in vision problems related to the nervous system and optic nerve—is best equipped to handle this complex diagnosis. Because ADOA is a rare genetic condition, not all specialists have deep experience treating patients with OPA1 gene mutations ^[1][2]. To ensure your care team has the necessary expertise, you need to ask direct questions about their patient panel, their approach to family screening, their knowledge of specialized imaging, and their connection to emerging therapies.

Assessing Their Direct OPA1 Experience

ADOA is the most common inherited optic neuropathy, but it is still rare, affecting about 1 in 12,000 to 1 in 25,000 people ^[3]. A true expert will not only know what ADOA is but will actively manage multiple patients with it across different stages of life.

• “How many OPA1 patients do you currently treat?” This will give you an immediate sense of whether they have seen the broad spectrum of how the disease presents and progresses over time ^[4].
• “Do you have experience managing childhood onset and family screening?” Because ADOA is “autosomal dominant,” a parent with the gene has a 50% chance of passing it to their children, and vision loss often begins in the first decade of life ^[3]. An expert will guide you through family screening and either manage pediatric patients directly or collaborate closely with pediatric specialists ^[5].
• “Are you experienced in screening for ‘ADOA-plus’ syndromes?” Some patients with OPA1 mutations develop extra-visual symptoms like hearing loss (hypoacusis), muscle weakness (myopathy), or balance issues ^[6][7]. Your specialist needs to recognize these risks and coordinate with audiologists, neurologists, or cardiologists to manage potential multisystem complications ^[8][9].

Questions About Testing and Monitoring

Standard eye charts do not capture the full impact of ADOA. An expert should use specific functional and structural tests to track both the physical nerve layers and your day-to-day visual experience ^[10].

• “How do you track functional vision changes like color vision and central blind spots?” ADOA classically causes specific functional issues, particularly blue-yellow color vision deficits and central visual field loss ^[1][2]. An expert will routinely use visual field testing and specialized color tests to map exactly how your usable vision is changing.
• “How will you use OCT to track my progression?” Structurally, an expert should specifically mention tracking the thickness of the ganglion cell-inner plexiform layer (GC-IPL) and the retinal nerve fiber layer (RNFL) using Optical Coherence Tomography (OCT), a non-invasive scan of the back of the eye ^[11][12].
• “Do you routinely recommend genetic testing?” Because inheritance patterns can sometimes be unclear, an expert will recommend working with a genetic counselor to confirm the exact variant of your OPA1 mutation ^[5][13].

Exploring Support, Treatments, and Clinical Trials

Currently, there is no approved cure for ADOA, meaning that functional support and staying informed on research are central to your care ^[14]. Your doctor should be proactive about maximizing your remaining vision and discussing off-label strategies safely.

• “Do you have a dedicated low-vision clinic or referral network?” Because ADOA causes irreversible vision loss, low-vision rehabilitation is a cornerstone of standard management. An expert will integrate functional support and assistive devices into your care plan to help you maintain independence.
• “Are you familiar with off-label mitochondrial support?” Because ADOA is characterized by mitochondrial dysfunction ^[15], some patients and doctors discuss supplements or medications like idebenone. Idebenone has shown potential in another condition called Leber’s Hereditary Optic Neuropathy (LHON), but a knowledgeable expert will honestly explain that equivalent clinical trial evidence for its efficacy in ADOA is currently lacking ^[16][17].
• “Can you help connect me with clinical trial registries?” Emerging therapies, including preclinical gene-modifying treatments and antisense oligonucleotides, are currently under investigation ^[14]. A proactive specialist will know how to navigate this landscape and help you find relevant research registries or observational studies.